-
06:17:44 PM

LLY Stock News

03/14/23 4:30 PM
NYSE : LLY
Lilly Announces Details of Presentations at 2023 American Association for Cancer Research (AACR) Annual Meeting
Eli Lilly and Company today announced that data from its oncology portfolio will be presented at the American Association for Cancer Research Annual Meeting in Orlando, April 14– 19, 2023. The presentations include the first clinical data from the Phase 1 studies of LY3537982 and LY3410738 and the Phase 2 study of Verzenio ® in metastatic treatment...
RHEA-AI
negative
03/06/23 10:30 AM
NYSE : LLY
Intensive education at clinics about multidisciplinary care improved likelihood that adults with type 2 diabetes and cardiovascular disease were receiving guideline-directed medicines, according to real-world study
The findings, from the COORDINATE-Diabetes trial, demonstrate the benefit of clinic-level educational interventions, including a focus on coordinating care between cardiology and diabetes care providers Results were presented at the Joint American College of Cardiology/ Journal of the American Medical Association Late-Breaking Clinical Trials...
RHEA-AI
neutral
03/03/23 2:58 PM
NYSE : LLY
U.S. FDA Broadens Indication for Verzenio® (abemaciclib) in HR+, HER2-, Node-Positive, High Risk Early Breast Cancer
Eli Lilly and Company today announced that the U.S. Food and Drug Administration approved an expanded indication for Verzenio ®, in combination with endocrine therapy, for the adjuvant treatment of adult patients with hormone receptor-positive, human epidermal growth factor receptor 2- negative, node-positive, early breast cancer at a high risk of...
RHEA-AI
very positive